LUC00028I2 - - Google Patents

Info

Publication number: LUC00028I2
Authority: LU; Luxembourg

Application number

LU00028C

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-20

Filing date

2017-07-12

Publication date

2017-09-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42061991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-07-12 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2017-07-14 Publication of LUC00028I1 publication Critical patent/LUC00028I1/fr

2017-09-25 Publication of LUC00028I2 publication Critical patent/LUC00028I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Diabetes (AREA)
Cell Biology (AREA)
Mycology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Toxicology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU00028C 2010-01-20 2017-07-12 LUC00028I2 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP10151239		2010-01-20
US38391410P	2010-09-17	2010-09-17
PCT/EP2011/050749 WO2011089183A2 (fr)	2010-01-20	2011-01-20	Antidotes d'anticoagulants
EP11703410.8A EP2525812B1 (fr)	2010-01-20	2011-01-20	Antidotes d'anticoagulants

Publications (2)

Publication Number	Publication Date
LUC00028I1 LUC00028I1 (fr)	2017-07-14
LUC00028I2 true LUC00028I2 (fr)	2017-09-25

Family

ID=42061991

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU00028C LUC00028I2 (fr)	2010-01-20	2017-07-12

Country Status (43)

Country	Link
US (3)	US8486398B2 (fr)
EP (2)	EP2525812B1 (fr)
JP (2)	JP5575923B2 (fr)
KR (1)	KR101781787B1 (fr)
CN (1)	CN102711813B (fr)
AP (1)	AP2012006242A0 (fr)
AR (1)	AR079944A1 (fr)
AU (1)	AU2011208719C1 (fr)
BR (1)	BR112012018021B1 (fr)
CA (1)	CA2787566A1 (fr)
CO (1)	CO6571889A2 (fr)
CY (2)	CY1118875T1 (fr)
DK (1)	DK2525812T3 (fr)
EA (1)	EA028371B1 (fr)
EC (1)	ECSP12012105A (fr)
ES (1)	ES2614992T3 (fr)
FR (1)	FR17C1026I2 (fr)
GE (1)	GEP20156341B (fr)
HK (1)	HK1173957A1 (fr)
HR (1)	HRP20170613T1 (fr)
HU (2)	HUE032263T2 (fr)
IL (1)	IL219427B (fr)
LT (2)	LT2525812T (fr)
LU (1)	LUC00028I2 (fr)
MA (1)	MA33936B1 (fr)
ME (1)	ME02602B (fr)
MX (1)	MX2012008360A (fr)
MY (1)	MY162323A (fr)
NL (1)	NL300882I2 (fr)
NO (2)	NO2017034I1 (fr)
NZ (1)	NZ599508A (fr)
PE (1)	PE20121516A1 (fr)
PL (1)	PL2525812T3 (fr)
PT (1)	PT2525812T (fr)
RS (1)	RS55683B1 (fr)
SG (1)	SG182552A1 (fr)
SI (1)	SI2525812T1 (fr)
TN (1)	TN2012000366A1 (fr)
TW (1)	TWI513466B (fr)
UA (1)	UA110470C2 (fr)
UY (1)	UY33196A (fr)
WO (1)	WO2011089183A2 (fr)
ZA (1)	ZA201202876B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR079944A1 (es) *	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante
ES2634098T3 (es)	2011-01-14	2017-09-26	The Regents Of The University Of California	Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
US20140050743A1 (en) *	2011-01-19	2014-02-20	Bayer Intellectual Property Gmbh	Binding proteins to inhibitors of coagulation factors
EA201301090A1 (ru) *	2011-03-30	2014-05-30	Бёрингер Ингельхайм Интернациональ Гмбх	Антидоты антикоагулянтов
PE20141295A1 (es)	2011-11-29	2014-10-01	Perosphere Inc	Agentes de reversion anticoagulante
US20140271660A1 (en)	2013-03-14	2014-09-18	Bayer Healthcare Llc	Monoclonal antibodies against antithrombin beta
WO2015059159A1 (fr) *	2013-10-25	2015-04-30	Boehringer Ingelheim International Gmbh	Antidotes à des anticoagulants
TW201623331A (zh) *	2014-03-12	2016-07-01	普羅帝納生物科學公司	抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CN105223348A (zh) *	2014-05-26	2016-01-06	北京九强生物技术股份有限公司	人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒
EP2980218A1 (fr)	2014-07-30	2016-02-03	Rheinische Friedrich-Wilhelms-Universität Bonn	Complexe de thrombine aptamère à utiliser comme antidote à action directe sur les inhibiteurs de la thrombine
US10501773B2 (en) *	2014-07-31	2019-12-10	Haemonetics Corporation	Detection and classification of an anticoagulant using a clotting assay
US10300154B2 (en)	2014-09-17	2019-05-28	David R Elmaleh	Anticoagulant derivatives for cardiovascular imaging
JP6581197B2 (ja)	2014-12-31	2019-09-25	深▲セン▼市薬欣生物科技有限公司ＳｈｅｎｚｈｅｎＰｈａｒｍａｃｉｎＣｏ．，Ｌｔｄ．	医薬組成物及びその製造方法
US10449195B2 (en)	2016-03-29	2019-10-22	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical formulation of palbociclib and a preparation method thereof
US11879014B2 (en)	2017-03-17	2024-01-23	Tusk Therapeutics Ltd.	Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
CN111511911B (zh) *	2017-12-24	2023-11-03	诺伊尔免疫生物科技株式会社	表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞
CR20200465A (es)	2018-03-13	2020-11-17	Tust Therapeutics Ltd	Agentes anticuerpos anti-cd25
CN112567244A (zh)	2018-05-11	2021-03-26	哈尔西恩治疗公司	靶向gasp-1颗粒的结合蛋白和嵌合抗原受体t细胞及其用途
WO2020092139A1 (fr)	2018-10-29	2020-05-07	Huahai Us Inc.	Nouveaux composés dipeptidiques et leurs utilisations
WO2020180489A1 (fr)	2019-03-06	2020-09-10	University Of Rochester	Compositions anticoagulantes et utilisations associées
CN114306245A (zh)	2020-09-29	2022-04-12	深圳市药欣生物科技有限公司	无定形固体分散体的药物组合物及其制备方法
TW202321311A (zh) *	2021-08-02	2023-06-01	日商諾伊爾免疫生物科技股份有限公司	與scFv等之連接子結合的抗體
US11446286B1 (en) *	2022-02-28	2022-09-20	King Faisal University	Treatment of fungal infections using dabigatran etexilate

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6087380A (en)	1949-11-24	2000-07-11	Boehringer Ingelheim Pharma Kg	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
EP0281604B1 (fr)	1986-09-02	1993-03-31	Enzon Labs Inc.	Molecules de liaison de chaines de polypeptide simples
DE68913658T3 (de)	1988-11-11	2005-07-21	Stratagene, La Jolla	Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
ATE151113T1 (de) *	1992-01-23	1997-04-15	Merck Patent Gmbh	Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE4203965A1 (de)	1992-02-11	1993-08-12	Max Planck Gesellschaft	Antidot fuer hirudin und synthetische thrombininhibitoren
ES2162823T5 (es)	1992-08-21	2010-08-09	Vrije Universiteit Brussel	Inmunoglobulinas desprovistas de cadenas ligeras.
US5837242A (en)	1992-12-04	1998-11-17	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
CA2163032C (fr)	1993-06-03	2001-02-06	John Landon	Fragments d'anticorps a des fins therapeutiques
AT404357B (de)	1995-06-13	1998-11-25	Immuno Ag	Prothrombin-derivate
DE19605126A1 (de)	1996-02-12	1997-08-14	Basf Ag	Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en)	1996-06-11	2001-03-13	Commonwealth Biotechnologies, Inc.	Heparin binding peptides
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
PE121699A1 (es) *	1997-02-18	1999-12-08	Boehringer Ingelheim Pharma	Heterociclos biciclicos disustituidos como inhibidores de la trombina
JP4187277B2 (ja)	1997-04-30	2008-11-26	エンゾンファーマシューティカルズ，インコーポレイテッド	グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用
DE19729544A1 (de) *	1997-07-10	1999-01-14	Basf Ag	Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung
US6440417B1 (en)	1998-11-06	2002-08-27	Conjuchem, Inc.	Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en)	1999-03-17	2003-09-23	The Regents Of The University Of Michigan	Protamine fragment compositions and methods of use
CA2405701A1 (fr)	2000-04-12	2001-10-25	Human Genome Sciences, Inc.	Proteines fusionnees a l'albumine
JP2004525620A (ja)	2001-01-17	2004-08-26	トルビオン・ファーマシューティカルズ・インコーポレイテッド	結合ドメイン−免疫グロブリン融合タンパク質
US20040097547A1 (en)	2001-04-16	2004-05-20	Taveras Arthur G.	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2004081026A2 (fr)	2003-06-30	2004-09-23	Domantis Limited	Polypeptides
US20070031438A1 (en) *	2001-12-10	2007-02-08	Junghans Richard P	Antibodies as chimeric effector cell receptors against tumor antigens
WO2003050531A2 (fr)	2001-12-11	2003-06-19	Algonomics N.V.	Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes
ES2263984T3 (es)	2002-06-28	2006-12-16	Domantis Limited	Ligandos doble-especificos con una vida media serica aumentada.
CA2505325C (fr)	2002-11-08	2014-02-25	Ablynx N.V.	Anticorps a domaine unique stabilises
PT3078743T (pt)	2007-09-28	2020-07-15	Portola Pharm Inc	Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
AR070141A1 (es) *	2008-01-23	2010-03-17	Glenmark Pharmaceuticals Sa	Anticuerpos humanizados especificos para el factor von willebrand
KR20120050457A (ko)	2009-08-24	2012-05-18	베링거 인겔하임 인터내셔날 게엠베하	다비가트란 이텍실레이트 과다복용에 대한 활성 차콜에 의한 응급 중재
AR079944A1 (es) *	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante

2011
- 2011-01-19 AR ARP110100179A patent/AR079944A1/es active IP Right Grant
- 2011-01-19 TW TW100102006A patent/TWI513466B/zh active
- 2011-01-20 BR BR112012018021-5A patent/BR112012018021B1/pt active IP Right Grant
- 2011-01-20 EP EP11703410.8A patent/EP2525812B1/fr active Active
- 2011-01-20 ME MEP-2017-29A patent/ME02602B/fr unknown
- 2011-01-20 KR KR1020127019086A patent/KR101781787B1/ko active IP Right Grant
- 2011-01-20 HU HUE11703410A patent/HUE032263T2/en unknown
- 2011-01-20 JP JP2012549355A patent/JP5575923B2/ja active Active
- 2011-01-20 UA UAA201209779A patent/UA110470C2/ru unknown
- 2011-01-20 DK DK11703410.8T patent/DK2525812T3/en active
- 2011-01-20 WO PCT/EP2011/050749 patent/WO2011089183A2/fr active Application Filing
- 2011-01-20 PL PL11703410T patent/PL2525812T3/pl unknown
- 2011-01-20 MY MYPI2012002840A patent/MY162323A/en unknown
- 2011-01-20 GE GEAP201112836A patent/GEP20156341B/en unknown
- 2011-01-20 RS RS20170195A patent/RS55683B1/sr unknown
- 2011-01-20 PE PE2012000997A patent/PE20121516A1/es active IP Right Grant
- 2011-01-20 CA CA2787566A patent/CA2787566A1/fr not_active Abandoned
- 2011-01-20 EP EP16205771.5A patent/EP3195876A1/fr not_active Withdrawn
- 2011-01-20 EA EA201201016A patent/EA028371B1/ru active Protection Beyond IP Right Term
- 2011-01-20 MA MA35080A patent/MA33936B1/fr unknown
- 2011-01-20 AP AP2012006242A patent/AP2012006242A0/xx unknown
- 2011-01-20 ES ES11703410.8T patent/ES2614992T3/es active Active
- 2011-01-20 US US13/010,403 patent/US8486398B2/en active Active
- 2011-01-20 AU AU2011208719A patent/AU2011208719C1/en active Active
- 2011-01-20 UY UY0001033196A patent/UY33196A/es active IP Right Grant
- 2011-01-20 LT LTEP11703410.8T patent/LT2525812T/lt unknown
- 2011-01-20 PT PT117034108T patent/PT2525812T/pt unknown
- 2011-01-20 MX MX2012008360A patent/MX2012008360A/es active IP Right Grant
- 2011-01-20 SG SG2012052445A patent/SG182552A1/en unknown
- 2011-01-20 NZ NZ599508A patent/NZ599508A/en unknown
- 2011-01-20 SI SI201131156A patent/SI2525812T1/sl unknown
- 2011-01-20 CN CN201180006616.4A patent/CN102711813B/zh active Active
2012
- 2012-04-19 ZA ZA2012/02876A patent/ZA201202876B/en unknown
- 2012-04-25 IL IL219427A patent/IL219427B/en active IP Right Grant
- 2012-07-18 TN TNP2012000366A patent/TN2012000366A1/en unknown
- 2012-07-23 CO CO12123109A patent/CO6571889A2/es active IP Right Grant
- 2012-08-14 EC ECSP12012105 patent/ECSP12012105A/es unknown
2013
- 2013-01-23 HK HK13101025.2A patent/HK1173957A1/xx unknown
- 2013-06-13 US US13/916,994 patent/US9034822B2/en active Active
2014
- 2014-07-02 JP JP2014136811A patent/JP2014210794A/ja active Pending
2015
- 2015-04-13 US US14/684,576 patent/US20150210778A1/en not_active Abandoned
2017
- 2017-03-22 CY CY20171100361T patent/CY1118875T1/el unknown
- 2017-04-14 HR HRP20170613TT patent/HRP20170613T1/hr unknown
- 2017-07-06 NL NL300882C patent/NL300882I2/nl unknown
- 2017-07-10 CY CY2017025C patent/CY2017025I1/el unknown
- 2017-07-10 FR FR17C1026C patent/FR17C1026I2/fr active Active
- 2017-07-10 LT LTPA2017021C patent/LTC2525812I2/lt unknown
- 2017-07-11 NO NO2017034C patent/NO2017034I1/no unknown
- 2017-07-12 LU LU00028C patent/LUC00028I2/fr unknown
- 2017-07-13 HU HUS1700030C patent/HUS1700030I1/hu unknown
2022
- 2022-08-12 NO NO2022036C patent/NO2022036I1/no unknown

Also Published As

Publication number	Publication date
BR112012018021B1 (pt)	2020-12-08
HUE032263T2 (en)	2017-09-28
HUS1700030I1 (hu)	2017-08-28
DK2525812T3 (en)	2017-02-27
ZA201202876B (en)	2012-12-27
JP2014210794A (ja)	2014-11-13
LT2525812T (lt)	2017-02-27
LUC00028I1 (fr)	2017-07-14
JP2013517317A (ja)	2013-05-16
EA028371B1 (ru)	2017-11-30
TWI513466B (zh)	2015-12-21
FR17C1026I2 (fr)	2018-07-20
AP2012006242A0 (en)	2012-04-30
TW201136606A (en)	2011-11-01
GEP20156341B (en)	2015-08-10
EP2525812A2 (fr)	2012-11-28
FR17C1026I1 (fr)	2017-09-08
NO2022036I1 (no)	2022-08-12
EP2525812B1 (fr)	2017-01-18
CN102711813B (zh)	2015-03-04
IL219427A0 (en)	2012-06-28
CO6571889A2 (es)	2012-11-30
MY162323A (en)	2017-05-31
EP3195876A1 (fr)	2017-07-26
PL2525812T3 (pl)	2017-07-31
LTC2525812I2 (lt)	2019-05-10
MA33936B1 (fr)	2013-01-02
CA2787566A1 (fr)	2011-07-28
NO2017034I1 (no)	2017-07-11
ES2614992T3 (es)	2017-06-02
HRP20170613T1 (hr)	2017-06-30
LTPA2017021I1 (lt)	2017-07-25
CY2017025I2 (el)	2017-11-14
ME02602B (fr)	2017-06-20
TN2012000366A1 (en)	2014-01-30
SG182552A1 (en)	2012-08-30
PE20121516A1 (es)	2012-11-24
RS55683B1 (sr)	2017-07-31
AU2011208719C1 (en)	2017-07-13
EA201201016A1 (ru)	2013-02-28
IL219427B (en)	2018-05-31
AU2011208719A1 (en)	2012-05-17
WO2011089183A3 (fr)	2011-11-17
US20130289248A1 (en)	2013-10-31
BR112012018021A2 (pt)	2017-06-20
KR101781787B1 (ko)	2017-09-26
CN102711813A (zh)	2012-10-03
MX2012008360A (es)	2012-08-08
UY33196A (es)	2011-08-31
KR20120128126A (ko)	2012-11-26
WO2011089183A2 (fr)	2011-07-28
US20120027780A1 (en)	2012-02-02
UA110470C2 (ru)	2016-01-12
JP5575923B2 (ja)	2014-08-20
PT2525812T (pt)	2017-04-26
NL300882I2 (nl)	2017-07-20
HK1173957A1 (en)	2013-05-31
CY1118875T1 (el)	2018-01-10
US20150210778A1 (en)	2015-07-30
CY2017025I1 (el)	2017-11-14
ECSP12012105A (es)	2012-10-30
NZ599508A (en)	2014-05-30
US8486398B2 (en)	2013-07-16
SI2525812T1 (sl)	2017-05-31
US9034822B2 (en)	2015-05-19
AR079944A1 (es)	2012-02-29

Publication	Publication Date	Title
LUC00028I2 (fr)	2017-09-25
BR112013008959A2 (fr)	2017-10-03
BR112012031500A2 (fr)	2015-11-17
BR112012029986A2 (fr)	2017-08-22
BR112012030039A2 (fr)	2017-09-05
BR112012028408A2 (fr)	2017-10-03
BR112012026492A2 (fr)	2017-09-05
BR112012027808A2 (fr)	2017-08-15
BR112012024897A2 (fr)	2017-08-22
BR112012025307A2 (fr)	2017-09-12
BR112012026946A2 (fr)	2017-10-03
BR112012025482A2 (fr)	2012-10-05
BR112013006400A2 (fr)	2021-12-07
BR112012031826A2 (fr)	2021-12-21
BR112012028186A2 (fr)	2017-08-15
BR112012025577A2 (fr)	2017-08-29
BR112012023249A2 (fr)	2017-08-15
BR112012027015A2 (fr)	2017-08-22
BR112012025308A2 (fr)	2017-08-29
BR112012027945A2 (fr)	2017-08-15
BR112012024872A2 (fr)	2017-08-15
BR112012023265A2 (fr)	2017-08-15
BR112013010949A2 (fr)	2017-09-05
BR112013003284A2 (fr)	2017-08-29
BR112013002646A2 (fr)	2013-02-04